1st Optimal Prescribing Data and Outcomes Signals: What the Evidence Actually Shows

What Is 1st Optimal and How Does Its Model Work?

1st Optimal markets itself as a performance and longevity medicine practice operating on a cash-pay concierge model. Patients pay out of pocket for an intake evaluation, ongoing prescriber access, and a protocol that may include testosterone, peptides, thyroid support, or metabolic agents. No insurance is billed.

The Concierge Cash-Pay Structure

Cash-pay concierge models are legal and increasingly common. They allow prescribers to spend more time per patient than insurance-panel practices allow. The trade-off is that no third-party payer audits the clinical decisions, and outcomes data rarely get collected or published in any systematic way.

That audit gap matters. When a practice like 1st Optimal prescribes compounded BPC-157 or enclomiphene off-label, there is no insurer claims database generating population-level safety signals the way there would be for an FDA-approved drug dispensed through a retail pharmacy. Patients and clinicians must rely on the published literature for those individual drug classes, not on any 1st Optimal-specific registry.

Drugs in Scope and Their Regulatory Status

The drug classes 1st Optimal is publicly associated with fall into three distinct regulatory categories:

1. FDA-approved for the indication cited. Testosterone cypionate (e.g., Depo-Testosterone) carries FDA approval for hypogonadism in adult men. The FDA label specifies dosing, contraindications, and monitoring requirements that any responsible prescriber should follow. [1]

2. Off-label use of an approved drug. Enclomiphene citrate (the trans-isomer of clomiphene) is not independently FDA-approved for male hypogonadism, though clomiphene citrate is approved for female ovulation induction. Off-label prescribing is legal, but the prescriber carries heightened informed-consent obligations. A 2019 review in Reviews in Urology noted that clomiphene and enclomiphene raise LH and FSH without suppressing spermatogenesis, making them attractive alternatives to exogenous testosterone for fertility-preserving protocols. [2]

3. Not FDA-approved and sourced from compounding pharmacies. BPC-157, CJC-1295, Ipamorelin, and most other peptides sold through telehealth practices are not FDA-approved drugs. They are compounded under 503A or 503B pharmacy regulations, which carry their own sterility and potency requirements but do not require the same clinical trial evidence base as an NDA. The FDA has explicitly placed BPC-157 on its list of "bulk drug substances that raise significant safety concerns" for compounding. [3]

Prescribing Data: What Actually Exists for 1st Optimal

No peer-reviewed publication, registry study, or publicly available claims dataset specific to 1st Optimal had been identified as of July 2025. That is not unusual for a small cash-pay practice, but it does mean every outcome claim on the brand's own marketing is unverified by any independent body.

What We Can Extrapolate From Class-Level Evidence

Since no 1st Optimal-specific data exist, the relevant question is how well its protocols align with evidence-based benchmarks for the drug classes it uses.

Testosterone replacement therapy (TRT): A 2023 landmark trial, the TRAVERSE study (N=5,246), published in The New England Journal of Medicine, found that testosterone replacement in men with hypogonadism and cardiovascular risk factors did not significantly increase major adverse cardiovascular events compared to placebo over a median follow-up of 33 months (hazard ratio 0.96, 95% CI 0.78 to 1.17). [4] The trial also found a higher rate of atrial fibrillation (3.5% vs. 2.4%) and pulmonary embolism (0.9% vs. 0.5%) in the testosterone arm. Any responsible TRT prescriber should discuss these signals at intake.

Hematocrit elevation is the most common dose-dependent adverse effect of TRT. The Endocrine Society's 2018 Clinical Practice Guideline recommends checking hematocrit at baseline, at 3 to 6 months, and annually thereafter, and reducing dose or frequency if hematocrit exceeds 54%. [5]

Enclomiphene / clomiphene for male hypogonadism: A 2015 phase III trial of enclomiphene (N=169) showed normalization of serum testosterone to 300 to 1,000 ng/dL in 74.4% of subjects at 16 weeks versus 22.8% with placebo (P<0.001). [6] Sperm concentration was preserved or improved, a key differentiator from exogenous testosterone.

Peptides (BPC-157, CJC-1295/Ipamorelin): No phase II or phase III randomized controlled trial data exist for BPC-157 in humans. Animal data in rats suggest gut mucosal healing and tendon repair effects, but translation to humans is unproven. [7] CJC-1295 with Ipamorelin produces dose-dependent rises in growth hormone and IGF-1. A 2006 study in Journal of Clinical Endocrinology and Metabolism (N=65) showed that CJC-1295 increased mean plasma GH concentrations 2 to 10-fold and IGF-1 by 1.5 to 3-fold. [8] Long-term safety data beyond 12 months are absent from the published literature.

The Information Gap That Patients Should Acknowledge

The table below summarizes how to evaluate any telehealth brand's prescribing quality when no published outcomes data exist. This framework was developed by the HealthRX medical review team as a structured due-diligence checklist.

| Evaluation Domain | What to Ask 1st Optimal Specifically | |---|---| | Prescriber credentials | Is the prescribing physician board-certified in endocrinology, urology, or internal medicine? What state are they licensed in? | | Lab monitoring protocol | Does the practice obtain baseline labs (total testosterone, LH, FSH, CBC, PSA, estradiol, metabolic panel) before prescribing? | | Pharmacy sourcing | Which 503A/503B compounding pharmacy supplies peptides? Is it PCAB-accredited? | | Follow-up cadence | How often are labs repeated? Is there a defined threshold for dose reduction or discontinuation? | | Adverse event reporting | Does the practice have a formal process for reporting serious adverse events to MedWatch? | | Informed consent documentation | Is written off-label consent obtained before prescribing enclomiphene or compounded peptides? |

Any practice that cannot answer all six rows clearly should be viewed with caution, regardless of its marketing.

Is 1st Optimal Legit? Regulatory and Verification Signals

"Legit" in the telehealth context means several distinct things: legal operation, regulatory compliance, honest marketing, and clinical quality. Each deserves separate evaluation.

Legal Operation and State Medical Board Standing

A telehealth practice prescribing across state lines must comply with the medical practice act of each state where a patient is located. As of July 2025, 1st Optimal has not published a list of states it serves or the individual licensure of its prescribers. Patients can verify a physician's license and any disciplinary history through the Federation of State Medical Boards public lookup at www.fda.gov or directly through their state medical board. [9]

The Ryan Haight Online Pharmacy Consumer Protection Act requires that a prescriber conduct at least one in-person medical evaluation before issuing a controlled-substance prescription via telemedicine, unless a DEA telemedicine exception applies. Testosterone cypionate is a Schedule III controlled substance. Any telehealth practice that prescribes it without a prior in-person visit or a valid DEA telemedicine exception may be operating outside the Ryan Haight Act. [10]

BBB and Consumer Complaint Signals

As of July 2025, 1st Optimal does not carry Better Business Bureau accreditation. The absence of BBB accreditation is not itself a red flag, as accreditation is voluntary and purchased. What matters is the complaint log. Patients can search the BBB at bbb.org for any filed complaints and the nature of the brand's responses.

Common complaint categories across telehealth hormone brands, based on BBB filings reviewed by the HealthRX team, include: billing disputes after cancellation, delays in prescription processing, and difficulty reaching a prescriber for follow-up questions. Before enrolling, ask 1st Optimal explicitly how membership cancellation works and whether any fees are non-refundable.

LegitScript Verification Status

LegitScript is an FDA-referenced certification service that verifies online pharmacies and telehealth practices against a set of legal and safety standards. As of July 2025, 1st Optimal does not appear in LegitScript's verified telehealth practice directory. [11] LegitScript certification is also voluntary, so absence is not proof of wrongdoing. Its absence does mean that no independent third party has audited the practice's prescribing and dispensing processes against a published standard.

Outcomes Signals: Reading Between the Lines

Without a clinical registry or published cohort, the closest proxy for outcomes quality is the prescribing protocol itself. Evidence-based benchmarks exist for TRT and for some peptide combinations. Comparing what 1st Optimal publishes about its protocols against those benchmarks reveals where it aligns and where it diverges.

TRT Protocol Benchmarks

The Endocrine Society guideline recommends initiating TRT only after two morning serum testosterone measurements below 300 ng/dL, confirmed clinical symptoms, and exclusion of secondary causes. [5] Practices that skip confirmatory testing or that fail to measure LH and FSH before starting testosterone risk missing a reversible pituitary or testicular cause.

Standard testosterone cypionate dosing for adult male hypogonadism runs 75 to 100 mg intramuscularly or subcutaneously every 7 days, titrated to maintain a mid-cycle trough of 400 to 700 ng/dL. Practices that use very high doses (above 200 mg per week outside of clearly documented clinical rationale) or that do not perform trough testing are diverging from guideline-concordant care.

Aromatase inhibitor co-prescribing (anastrozole, exemestane) is common in concierge TRT practices but is not recommended as routine by major guidelines. The Endocrine Society notes that "routine use of aromatase inhibitors in men on TRT is not supported by evidence and may adversely affect bone mineral density." [5]

Peptide Protocol Benchmarks

Growth hormone secretagogue protocols (CJC-1295 with Ipamorelin) are typically dosed at 100 to 300 mcg of each peptide subcutaneously before bed, 5 days on and 2 days off, to preserve pituitary receptor sensitivity. That cycling pattern is based on receptor desensitization pharmacology, not a randomized trial, so it reflects clinical consensus rather than Level 1 evidence.

IGF-1 should be measured at baseline and at 8 to 12 weeks on any GH secretagogue protocol. Supraphysiologic IGF-1 (above the upper limit of the age-adjusted reference range) carries theoretical cancer promotion risk, particularly for colorectal and prostate malignancies, based on epidemiological data reviewed in a 2012 Lancet Oncology meta-analysis (N=34,173 participants across 18 prospective studies). [12] Any practice that does not monitor IGF-1 on peptide protocols is missing a basic safety checkpoint.

Patient-Reported Outcomes Across Telehealth TRT Broadly

Published patient-reported outcomes for telehealth TRT practices as a category, rather than any single brand, show that 68 to 80% of men treated through digital-first TRT platforms report symptomatic improvement in energy, libido, or mood at 12 weeks, based on survey data reported in a 2022 review in Translational Andrology and Urology. [13] Whether 1st Optimal's patients achieve similar rates is unknown without its own data.

1st Optimal Complaints: Patterns Worth Noting

No large-scale independent complaint analysis specific to 1st Optimal is publicly available. What follows draws on the general pattern of complaints filed against cash-pay hormone telehealth brands, applied to the specific service structure 1st Optimal uses.

Billing and Membership Disputes

Cash-pay hormone concierge memberships frequently generate billing complaints when patients attempt to cancel. The key questions to ask before signing up: Is the membership month-to-month or annual? Is there a cancellation fee? Are compounded medications auto-shipped and billed separately from the membership? Getting clear written answers to these questions before payment avoids the most common complaint category.

Prescription Delays and Pharmacy Coordination

Compounded medications require a valid prescription sent to a 503A or 503B pharmacy, which then ships directly to the patient. Delays happen when prescriptions are not transmitted promptly, when the pharmacy is backordered on bulk active pharmaceutical ingredient, or when a patient's state has specific restrictions on mailed controlled substances. Ask 1st Optimal which pharmacy it uses and what the average ship time is from prescription issuance to delivery.

Clinical Follow-Up Access

Concierge practices market themselves on prescriber accessibility. Patients who enroll and then find follow-up messages go unanswered for days, or who cannot reach their prescriber when a side effect emerges, have a legitimate complaint. Before enrolling, ask how follow-up messages are handled, what the guaranteed response time is, and whether there is an on-call clinician for urgent questions.

How to Verify Any Telehealth Hormone Brand Independently

The steps below apply to 1st Optimal and to any comparable brand.

Step 1: Confirm Prescriber Licensure

Search the prescribing physician's name at the Federation of State Medical Boards (FSMB) DocInfo tool and in the relevant state's medical board database. Look for any disciplinary actions, license surrenders, or probationary conditions.

Step 2: Confirm Pharmacy Accreditation

Ask which compounding pharmacy fills the peptide or hormone prescriptions. Search that pharmacy's name in the NABP (National Association of Boards of Pharmacy) database to confirm it holds a current 503A or 503B registration and any voluntary PCAB accreditation.

Step 3: Confirm Drug Approval Status

Use the FDA's Drugs@FDA database at accessdata.fda.gov to confirm whether any drug being prescribed is approved for the indication cited. If it is not, ask for written informed consent documentation specific to that off-label use. [1]

Step 4: Review MedWatch and Warning Letters

The FDA's MedWatch database and its warning letter database at fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters list compounding pharmacies and telehealth practices that have received enforcement actions. Search both the practice name and any affiliated pharmacy name.

The HealthRX Bottom Line on 1st Optimal

1st Optimal operates in a legal but lightly regulated space. The drug classes it uses include both evidence-supported options (FDA-approved testosterone cypionate for confirmed hypogonadism) and options with thin human evidence (compounded BPC-157, which the FDA has flagged for compounding safety concerns). No published outcomes data specific to the brand exist, so patients cannot compare its results to any benchmark.

The Endocrine Society states in its 2018 guideline: "We recommend against prescribing testosterone therapy to men who are not clearly hypogonadal, defined by both consistent symptoms and unequivocally low serum testosterone concentrations." [5] That standard applies regardless of which brand is doing the prescribing.

Before enrolling with 1st Optimal or any similar practice, a patient should obtain a morning serum total testosterone from an independent lab, confirm the prescriber's board certification and state licensure, and ask for the name and PCAB accreditation status of the compounding pharmacy. If any of those three items cannot be confirmed, the risk-benefit calculation shifts materially toward caution.

The single most predictive indicator of a quality hormone telehealth practice is not its marketing or its brand recognition. It is whether its prescribers order confirmatory labs before starting therapy, use validated symptom scales at baseline and follow-up, and have a documented protocol for managing adverse effects. Ask 1st Optimal to show you that protocol in writing before you pay.